HIV drug resistance , Users Manual
December 2017
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
Meeting Report
Bangkok, Thailand 8-11 August 2016
You can download the report in Englisch and French. Summaries available in Arabic, Amharic, Dari, Tigrinya, Pashto
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
The report explores strategies for sustaining the country’s responses to the three diseases and eventually transitioning away from external funding and programmatic support. It takes stock of Kenya’s health financing landscape and identifies opportunities and challenges for sustaining effective ...coverage of HIV, TB, and malaria services in the long run, mindful of macro-fiscal and institutional constraints. The report informs ongoing dialogue within government, including among the Ministry of Health, National Treasury, Council of Governors, and National AIDS Control Council, as well as between government and development partners.
more
Global HIV Strategic Information Working Group
Development of IEC materials for the NDoH launch of oral PrEP at selected sex worker sites in South Africa
National Tuberculosis and Leprosy Conrol Programme
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more